Alexander G. Asam
Direktor/Vorstandsmitglied bei APR Applied Pharma Research SA
Vermögen: - $ am 31.05.2024
Profil
Alexander G.
Asam is currently a Director at Autonomic Technologies, Inc. and a Non-Executive Director at APR Applied Pharma Research SA. He is also an Investment Advisor at HBM Partners AG, and a Member-Observers Board at both Corvidia Therapeutics, Inc. and Swixx Biopharma SA. In his former positions, Dr. Asam served as the Chairman-Supervisory Board at Avontec GmbH and as a Director at Sublimity Therapeutics Ltd.
He was also an Independent Director at Arcutis Biotherapeutics, Inc. from 2019 to 2020, and at Mineralys Therapeutics, Inc. from 2021 to 2024.
Additionally, he worked as a Principal at Hoechst AG and Aventis SA, and as a Managing Partner at DVC Deutsche Venture Capital from 2001 to 2007.
Dr. Asam was a Member-Supervisory Board at Curetis GmbH, Head-Investor Relations at Lion Bioscience AG, and a Member-Observers Board at Vitaeris, Inc.Dr. Asam obtained an MBA from the University of Amsterdam, and completed his graduate and doctorate degrees at Ruprecht-Karls-Universität Heidelberg.
He also holds an MBA from the University of Aston.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 09.02.2023 | 0 ( -.--% ) | - $ | 31.05.2024 |
Aktive Positionen von Alexander G. Asam
| Unternehmen | Position | Beginn |
|---|---|---|
HBM Partners AG
 HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Private Equity Investor | 01.01.2007 |
APR Applied Pharma Research SA
 APR Applied Pharma Research SA BiotechnologyHealth Technology APR Applied Pharma Research SA develops and licenses healthcare products and technologies. It specializes in the development of oral and topical formulations in various healthcare regulatory areas ranging from Rx and OTC pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. The company was founded in 1990 and is headquartered in Balerna, Switzerland. | Direktor/Vorstandsmitglied | - |
Autonomic Technologies, Inc.
 Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Direktor/Vorstandsmitglied | - |
Corvidia Therapeutics, Inc.
 Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Corporate Officer/Principal | - |
Swixx Biopharma SA
 Swixx Biopharma SA BiotechnologyHealth Technology Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Alexander G. Asam
| Unternehmen | Position | Ende |
|---|---|---|
| MINERALYS THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 22.05.2024 |
| ARCUTIS BIOTHERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 02.11.2020 |
DVC Deutsche Venture Capital
 DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | Private Equity Investor | 11.10.2007 |
Vitaeris, Inc.
 Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Corporate Officer/Principal | - |
| ░░░░░░░░░ ░░░░░░░░░░░░ ░░░░ | ░░░░░░░░░░░░░░░░░░░░░░░░░░ | - |
Ausbildung von Alexander G. Asam
| University of Amsterdam | Masters Business Admin |
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
| University of Aston | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| ARCUTIS BIOTHERAPEUTICS, INC. | Health Technology |
| MINERALYS THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 13 |
|---|---|
Hoechst AG
 Hoechst AG Chemicals: Major DiversifiedProcess Industries Hoechst AG produced specialty chemicals and pharmaceutical products. It products ranged in areas of heart cycle, thrombose, central nervous system, onkologie, diabetes, metabolic illnesses, internal medicine and vaccines. Founded in 1863, the company was headquartered in Frankfurt am Main, Germany. | Process Industries |
Aventis SA
 Aventis SA Pharmaceuticals: MajorHealth Technology Aventis SA develops pharmaceuticals and vaccines for preventative medicine. The company is located in Schiltigheim, France. | Health Technology |
HBM Partners AG
HBM Partners AG Investment ManagersFinance HBM Partners AG (HBM-P) was established in 2001 as an independent provider of investment advisory services with headquarters in Zug, Switzerland. HBM-P's field of expertise comprises global human medicine, biotechnology, medical technology and related sectors. The firm primarily advises HBM BioVentures AG and HBM BioCapital via their Cayman Islands-based, wholly-owned subsidiary, HBM Partners (Cayman) Ltd., which acts as the investment manager for the HBM funds. They rely on the services of an external consultant to analyze investment opportunities in the US. | Finance |
Autonomic Technologies, Inc.
Autonomic Technologies, Inc. Electronic Equipment/InstrumentsElectronic Technology Autonomic Technologies, Inc. develops and commercializes innovative therapies for the treatment of severe headache. Its product, the ATI Neurostimulation System, is used for the treatment of acute pain of cluster headache. The company was founded in 2007 and is headquartered in Redwood City, CA. | Electronic Technology |
DVC Deutsche Venture Capital
DVC Deutsche Venture Capital Investment ManagersFinance DVC Deutsche Venture Capital (DVC) is an independent venture capital firm focused on science-based sectors. DVC was established in 1998 and is based in Munich. The firm operates in partnership with Deutsche Bank AG (FR: DBK; NYSE: DB). | Finance |
Avontec GmbH
 Avontec GmbH Pharmaceuticals: MajorHealth Technology Avontec is a Phase 2 biopharmaceutical company focused on the development and commercialization of novel therapeutic treatments for inflammatory disease. Its clinical development programs include product candidates for multiple potential inflammatory indications. The two most advanced, AVT-01 in asthma and AVT-02 in psoriasis, have successfully advanced into Phase 2a clinical trials that the firm expects to be completed until the first half of 2008. In addition, there are several candidates in the pipeline based on Avontec's core decoy technology. Avontec operates based on a lean business model with a seasoned management team experienced in clinical development. | Health Technology |
Curetis GmbH
 Curetis GmbH Medical SpecialtiesHealth Technology Curetis GmbH operates as a molecular diagnostics company which focuses on the development and commercialization of products for diagnosing severe infectious diseases. The firm offers diagnostic solutions for hospitals and large-scale laboratories. Its products include Unyvero L4 Lysator, Unyvero C8 Cockpit, Unyvero A50 Analyzer, and Unyvero Application Cartridges. The company was founded by Andreas Boos, Johannes Bacher, Gerd Lüdke, and Anne Thews in August 2007 and is headquartered in Holzgerlingen, Germany. | Health Technology |
APR Applied Pharma Research SA
APR Applied Pharma Research SA BiotechnologyHealth Technology APR Applied Pharma Research SA develops and licenses healthcare products and technologies. It specializes in the development of oral and topical formulations in various healthcare regulatory areas ranging from Rx and OTC pharmaceuticals, nutraceuticals, dermocosmetics, and medical devices. The company was founded in 1990 and is headquartered in Balerna, Switzerland. | Health Technology |
| Lion Bioscience AG | |
Sublimity Therapeutics Ltd.
 Sublimity Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Sublimity Therapeutics Ltd. develops and manufactures pharmaceutical products. It engages in the development of gastrointestinal and immunological therapeutics. The firm’s lead product, CyCol, harnesses the powerful efficacy of the known immunosuppressive drug, cyclosporine in a safer format by targeting drug release towards the site of diseased tissue in the colon of patients with ulcerative colitis. Its other products include CyCron, AlloCol, CyLow, oral vaccines and oral peptides. The company was founded by Ivan Coulter in 2003 and is headquartered in Dublin, Ireland. | Health Technology |
Corvidia Therapeutics, Inc.
Corvidia Therapeutics, Inc. BiotechnologyHealth Technology Corvidia Therapeutics, Inc. is a biotechnology company focusing on cardiovascular therapies. It develops treatments for atherosclerotic cardiovascular disease, inflammation in chronic kidney diseases, and high triglyceride-induced acute pancreatitis. The company was founded by Michael H. Davidson, Rahul Kakkar, Matt Devalaraja, and Ram Aiyar in 2015 and is headquartered in Waltham, MA. | Health Technology |
Vitaeris, Inc.
Vitaeris, Inc. BiotechnologyHealth Technology Vitaeris, Inc. develops new treatment options for chronic inflammatory diseases. The company was founded by Kevin Chow, Patrick A. Robinson and Noel F. Hall in 2016 and is headquartered in Vancouver, Canada. | Health Technology |
Swixx Biopharma SA
Swixx Biopharma SA BiotechnologyHealth Technology Swixx Biopharma SA provides marketing and sales, regulatory, medical affairs, cold chain, logistic services to pharmaceutical companies. Its services also include receivables, collection, FX coverage, risk management, compliance, and reimbursement and market access. The company was founded by Petr Nemec and Robert Stuart Swanson in 2013 and is headquartered in Baar, Switzerland. | Health Technology |
